CA2616125A1 - Thymosine .beta.4 oxydee tronquee et derives de celle-ci - Google Patents

Thymosine .beta.4 oxydee tronquee et derives de celle-ci Download PDF

Info

Publication number: CA2616125A1
Authority: CA; Canada
Prior art keywords: oxidized; thymosin; disease; truncated; peptide
Prior art date: 2005-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002616125A

Other languages

English (en)

Inventor

Elizabeth Taylor

Robert Goodenow

John Young

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GRANNUS BIOSCIENCES

Original Assignee

GRANNUS BIOSCIENCES

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-19

Filing date

2006-07-19

Publication date

2007-01-25

2006-07-19 Application filed by GRANNUS BIOSCIENCES filed Critical GRANNUS BIOSCIENCES

2007-01-25 Publication of CA2616125A1 publication Critical patent/CA2616125A1/fr

Status Abandoned legal-status Critical Current

Links

108010079996 thymosin beta(4) Proteins 0.000 title claims abstract 4
201000010099 disease Diseases 0.000 claims abstract description 29
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
206010061218 Inflammation Diseases 0.000 claims abstract description 12
230000004054 inflammatory process Effects 0.000 claims abstract description 12
108090000765 processed proteins & peptides Proteins 0.000 claims description 60
230000000694 effects Effects 0.000 claims description 36
239000000203 mixture Substances 0.000 claims description 36
229930182817 methionine Natural products 0.000 claims description 19
238000000034 method Methods 0.000 claims description 19
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 16
208000027418 Wounds and injury Diseases 0.000 claims description 15
206010052428 Wound Diseases 0.000 claims description 13
150000001413 amino acids Chemical class 0.000 claims description 13
210000001519 tissue Anatomy 0.000 claims description 10
208000017520 skin disease Diseases 0.000 claims description 7
201000004624 Dermatitis Diseases 0.000 claims description 6
230000000302 ischemic effect Effects 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
201000003883 Cystic fibrosis Diseases 0.000 claims description 4
206010014989 Epidermolysis bullosa Diseases 0.000 claims description 4
208000010668 atopic eczema Diseases 0.000 claims description 4
238000006243 chemical reaction Methods 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
230000002757 inflammatory effect Effects 0.000 claims description 4
208000010125 myocardial infarction Diseases 0.000 claims description 4
208000006934 radiodermatitis Diseases 0.000 claims description 4
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
206010012442 Dermatitis contact Diseases 0.000 claims description 3
201000004681 Psoriasis Diseases 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 3
230000002500 effect on skin Effects 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
210000000056 organ Anatomy 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
208000023504 respiratory system disease Diseases 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
230000009885 systemic effect Effects 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
208000002506 Darier Disease Diseases 0.000 claims description 2
206010011985 Decubitus ulcer Diseases 0.000 claims description 2
206010012438 Dermatitis atopic Diseases 0.000 claims description 2
206010048768 Dermatosis Diseases 0.000 claims description 2
206010056340 Diabetic ulcer Diseases 0.000 claims description 2
208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
208000011200 Kawasaki disease Diseases 0.000 claims description 2
208000002260 Keloid Diseases 0.000 claims description 2
208000004210 Pressure Ulcer Diseases 0.000 claims description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
206010039705 Scleritis Diseases 0.000 claims description 2
206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
208000025865 Ulcer Diseases 0.000 claims description 2
208000000558 Varicose Ulcer Diseases 0.000 claims description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
230000000172 allergic effect Effects 0.000 claims description 2
201000008937 atopic dermatitis Diseases 0.000 claims description 2
208000024908 graft versus host disease Diseases 0.000 claims description 2
208000006454 hepatitis Diseases 0.000 claims description 2
231100000283 hepatitis Toxicity 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
208000001875 irritant dermatitis Diseases 0.000 claims description 2
208000028867 ischemia Diseases 0.000 claims description 2
210000001117 keloid Anatomy 0.000 claims description 2
201000004607 keratosis follicularis Diseases 0.000 claims description 2
201000011486 lichen planus Diseases 0.000 claims description 2
208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
230000033667 organ regeneration Effects 0.000 claims description 2
208000007578 phototoxic dermatitis Diseases 0.000 claims description 2
230000002829 reductive effect Effects 0.000 claims description 2
208000037803 restenosis Diseases 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
208000008742 seborrheic dermatitis Diseases 0.000 claims description 2
230000009759 skin aging Effects 0.000 claims description 2
230000017423 tissue regeneration Effects 0.000 claims description 2
238000002054 transplantation Methods 0.000 claims description 2
231100000397 ulcer Toxicity 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims 2
208000006673 asthma Diseases 0.000 claims 2
230000001684 chronic effect Effects 0.000 claims 2
230000002526 effect on cardiovascular system Effects 0.000 claims 2
206010014561 Emphysema Diseases 0.000 claims 1
241000792859 Enema Species 0.000 claims 1
206010063837 Reperfusion injury Diseases 0.000 claims 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
208000010247 contact dermatitis Diseases 0.000 claims 1
230000002183 duodenal effect Effects 0.000 claims 1
239000007920 enema Substances 0.000 claims 1
229940095399 enema Drugs 0.000 claims 1
230000002496 gastric effect Effects 0.000 claims 1
238000001361 intraarterial administration Methods 0.000 claims 1
238000007917 intracranial administration Methods 0.000 claims 1
238000007912 intraperitoneal administration Methods 0.000 claims 1
238000007913 intrathecal administration Methods 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 13
238000002560 therapeutic procedure Methods 0.000 abstract description 6
102000007501 Thymosin Human genes 0.000 description 132
108010046075 Thymosin Proteins 0.000 description 132
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 130
210000004027 cell Anatomy 0.000 description 33
102000004196 processed proteins & peptides Human genes 0.000 description 27
210000000440 neutrophil Anatomy 0.000 description 24
150000001875 compounds Chemical class 0.000 description 23
238000009472 formulation Methods 0.000 description 19
102000007469 Actins Human genes 0.000 description 17
235000006109 methionine Nutrition 0.000 description 17
108010085238 Actins Proteins 0.000 description 16
150000003431 steroids Chemical class 0.000 description 16
239000002245 particle Substances 0.000 description 15
108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
102100040247 Tumor necrosis factor Human genes 0.000 description 13
239000000443 aerosol Substances 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 12
229940024606 amino acid Drugs 0.000 description 12
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 12
230000012292 cell migration Effects 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
239000004615 ingredient Substances 0.000 description 10
230000029663 wound healing Effects 0.000 description 10
102000004127 Cytokines Human genes 0.000 description 9
108090000695 Cytokines Proteins 0.000 description 9
238000003556 assay Methods 0.000 description 9
210000005259 peripheral blood Anatomy 0.000 description 9
239000011886 peripheral blood Substances 0.000 description 9
230000019254 respiratory burst Effects 0.000 description 9
239000007787 solid Substances 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000007788 liquid Substances 0.000 description 8
210000001616 monocyte Anatomy 0.000 description 8
230000005012 migration Effects 0.000 description 7
238000013508 migration Methods 0.000 description 7
230000000770 proinflammatory effect Effects 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
102000004169 proteins and genes Human genes 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
239000000243 solution Substances 0.000 description 7
239000006228 supernatant Substances 0.000 description 7
230000006907 apoptotic process Effects 0.000 description 6
239000003814 drug Substances 0.000 description 6
230000006870 function Effects 0.000 description 6
FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 6
239000003921 oil Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
125000003275 alpha amino acid group Chemical group 0.000 description 5
230000027455 binding Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
239000006071 cream Substances 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
239000003925 fat Substances 0.000 description 5
235000019197 fats Nutrition 0.000 description 5
210000002683 foot Anatomy 0.000 description 5
229920006008 lipopolysaccharide Polymers 0.000 description 5
230000033001 locomotion Effects 0.000 description 5
230000003647 oxidation Effects 0.000 description 5
238000007254 oxidation reaction Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000003826 tablet Substances 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
230000003110 anti-inflammatory effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000000679 carrageenan Substances 0.000 description 4
235000010418 carrageenan Nutrition 0.000 description 4
229920001525 carrageenan Polymers 0.000 description 4
229940113118 carrageenan Drugs 0.000 description 4
230000006378 damage Effects 0.000 description 4
229960003957 dexamethasone Drugs 0.000 description 4
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
229940126864 fibroblast growth factor Drugs 0.000 description 4
238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000003226 mitogen Substances 0.000 description 4
238000006116 polymerization reaction Methods 0.000 description 4
230000009919 sequestration Effects 0.000 description 4
210000003491 skin Anatomy 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000013598 vector Substances 0.000 description 4
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
206010040070 Septic Shock Diseases 0.000 description 3
229930006000 Sucrose Natural products 0.000 description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
238000007792 addition Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 3
-1 cachets Substances 0.000 description 3
239000013553 cell monolayer Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000013642 negative control Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
239000012071 phase Substances 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000008439 repair process Effects 0.000 description 3
230000036303 septic shock Effects 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000005720 sucrose Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
201000004384 Alopecia Diseases 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000002151 Microfilament Proteins Human genes 0.000 description 2
108010040897 Microfilament Proteins Proteins 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
101100281510 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) met-6 gene Proteins 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
101800004196 Peptide P4 Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
206010047115 Vasculitis Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000000747 cardiac effect Effects 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
SXTAYKAGBXMACB-UHFFFAOYSA-N methionine sulfoximine Chemical compound CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 2
238000000465 moulding Methods 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
230000004983 pleiotropic effect Effects 0.000 description 2
HZEBHPIOVYHPMT-UHFFFAOYSA-N polonium atom Chemical compound [Po] HZEBHPIOVYHPMT-UHFFFAOYSA-N 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000013641 positive control Substances 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
241000894007 species Species 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
150000003462 sulfoxides Chemical class 0.000 description 2
230000008961 swelling Effects 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
230000000451 tissue damage Effects 0.000 description 2
231100000827 tissue damage Toxicity 0.000 description 2
210000003606 umbilical vein Anatomy 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
SFAAOBGYWOUHLU-UHFFFAOYSA-N 2-ethylhexyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC SFAAOBGYWOUHLU-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
206010001889 Alveolitis Diseases 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
102000000412 Annexin Human genes 0.000 description 1
108050008874 Annexin Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000035484 Cellulite Diseases 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012441 Dermatitis bullous Diseases 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
206010018698 Granuloma skin Diseases 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
208000024781 Immune Complex disease Diseases 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
208000004575 Infectious Arthritis Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
239000004365 Protease Substances 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 description 1
RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004141 Sodium laurylsulphate Substances 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
108700012920 TNF Proteins 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
150000001510 aspartic acids Chemical class 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000002479 balanitis Diseases 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000036232 cellulite Effects 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000014564 chemokine production Effects 0.000 description 1
201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
201000009805 cryptogenic organizing pneumonia Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
201000010251 cutis laxa Diseases 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
230000004665 defense response Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
208000032618 granuloma faciale Diseases 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
230000004217 heart function Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000009097 homeostatic mechanism Effects 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
239000012642 immune effector Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000003116 impacting effect Effects 0.000 description 1
230000006882 induction of apoptosis Effects 0.000 description 1
230000007574 infarction Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
239000002085 irritant Substances 0.000 description 1
231100000021 irritant Toxicity 0.000 description 1
229940078545 isocetyl stearate Drugs 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
108010028309 kalinin Proteins 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
230000036284 oxygen consumption Effects 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000008251 pharmaceutical emulsion Substances 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
229910052699 polonium Inorganic materials 0.000 description 1
201000006292 polyarteritis nodosa Diseases 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
208000009169 relapsing polychondritis Diseases 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
210000003019 respiratory muscle Anatomy 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
230000037390 scarring Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229960002718 selenomethionine Drugs 0.000 description 1
201000001223 septic arthritis Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
125000004354 sulfur functional group Chemical group 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229910052714 tellurium Inorganic materials 0.000 description 1
PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000003582 thrombocytopenic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940042130 topical foam Drugs 0.000 description 1
229940042129 topical gel Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000008733 trauma Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000006433 tumor necrosis factor production Effects 0.000 description 1
208000025883 type III hypersensitivity disease Diseases 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000003156 vasculitic effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002616125A 2005-07-19 2006-07-19 Thymosine .beta.4 oxydee tronquee et derives de celle-ci Abandoned CA2616125A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US70064105P	2005-07-19	2005-07-19
US60/700,641		2005-07-19
PCT/US2006/028323 WO2007012066A2 (fr)	2005-07-19	2006-07-19	Thymosine ?4 oxydee tronquee et derives de celle-ci

Publications (1)

Publication Number	Publication Date
CA2616125A1 true CA2616125A1 (fr)	2007-01-25

Family

ID=37669572

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002616125A Abandoned CA2616125A1 (fr)	2005-07-19	2006-07-19	Thymosine .beta.4 oxydee tronquee et derives de celle-ci

Country Status (4)

Country	Link
EP (1)	EP1913013A2 (fr)
AU (1)	AU2006269852A1 (fr)
CA (1)	CA2616125A1 (fr)
WO (1)	WO2007012066A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2260106A4 (fr) *	2008-03-17	2011-04-20	Regenerx Biopharmaceuticals	Fragments améliorés de bêta thymosine
EP3744729B1 (fr) *	2009-01-16	2023-03-01	Sederma	Peptides, compositions comprenant ces derniers et leurs utilisations dans les domaines cosmétique et dermopharmaceutique

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9806632D0 (en) *	1998-03-28	1998-05-27	Stevenson Robert	Peptide factor

2006
- 2006-07-19 EP EP06788075A patent/EP1913013A2/fr not_active Ceased
- 2006-07-19 CA CA002616125A patent/CA2616125A1/fr not_active Abandoned
- 2006-07-19 AU AU2006269852A patent/AU2006269852A1/en not_active Abandoned
- 2006-07-19 WO PCT/US2006/028323 patent/WO2007012066A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2007012066A3 (fr)	2007-06-07
AU2006269852A1 (en)	2007-01-25
EP1913013A2 (fr)	2008-04-23
WO2007012066A2 (fr)	2007-01-25

Publication	Publication Date	Title
ES2468318T3 (es)	2014-06-16	FSH recombinante que incluye sialilaci�n en alfa 2,3- y alfa 2,6
ES2289778T3 (es)	2008-02-01	Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii.
US20090317457A1 (en)	2009-12-24	Anti-inflammatory and wound healing effects of lymphoid thymosin b-4
JP7374527B2 (ja)	2023-11-07	α１－アンチトリプシン（ＡＡＴ）を発現する遺伝子改変された間葉系幹細胞
EP1094833B1 (fr)	2003-02-12	Thymosine beta 4 oxydee
KR20070017366A (ko)	2007-02-09	관절염증 치료제 또는 예방제
EA005005B1 (ru)	2004-10-28	ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
EA010200B1 (ru)	2008-06-30	Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
PT1887016E (pt)	2009-02-20	Fragmentos de gonadotropina coriónica humana (hcg) como imunorregulador
EA007967B1 (ru)	2007-02-27	Защита, восстановление и усиление эритропоэтинреактивных клеток, тканей и органов
CA2807552A1 (fr)	2012-02-09	Acides nucleiques modifies et leurs procedes d'utilisation
JPH10511557A (ja)	1998-11-10	血管内皮細胞増殖因子の変種、それらの使用およびそれらの生産法
KR20230023059A (ko)	2023-02-16	인슐린 저항성에 대한 개선된 펩티드 제약
CN101389650A (zh)	2009-03-18	包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
JP2009073845A (ja)	2009-04-09	ミエリン会合糖タンパク質（ｍａｇ）およびそのインヒビターを用いた組成物および方法
WO2005094890A1 (fr)	2005-10-13	Composition pour augmenter la stature
JP2013530148A (ja)	2013-07-25	組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途
EP0673384A1 (fr)	1995-09-27	Polypeptides utiles pour traiter des troubles inflammatoires
US10898550B2 (en)	2021-01-26	Compositions and methods of treating root avulsion injury
KR20110091720A (ko)	2011-08-12	Ｃｒｈｒ2 펩티드 작용제 및 이의 용도
CA2616125A1 (fr)	2007-01-25	Thymosine .beta.4 oxydee tronquee et derives de celle-ci
JPH08511172A (ja)	1996-11-26	血管障害の遺伝子治療に用いるためのｄｎａ発現ベクター
US10130687B2 (en)	2018-11-20	Compositions and methods for the treatment of orthopedic disease or injury
CN116004725A (zh)	2023-04-25	间充质干细胞在疼痛相关疾病中的应用
WO2019168914A1 (fr)	2019-09-06	Cellules t modifiées par irf-4 et leurs utilisations dans le traitement du cancer

Legal Events

Date	Code	Title	Description
2010-07-19	FZDE	Discontinued